Cargando…
A novel bispecific antibody targeting CD3 and prolactin receptor (PRLR) against PRLR-expression breast cancer
BACKGROUND: Prolactin receptor (PRLR) is highly expressed in a subset of human breast cancer and prostate cancer, which makes it a potential target for cancer treatment. In clinical trials, the blockade of PRLR was shown to be safe but with poor efficacy. It is therefore urgent to develop new therap...
Autores principales: | Zhou, Yuexian, Zong, Huifang, Han, Lei, Xie, Yueqing, Jiang, Hua, Gilly, John, Zhang, Baohong, Lu, Huili, Chen, Jie, Sun, Rui, Pan, Zhidi, Zhu, Jianwei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7216678/ https://www.ncbi.nlm.nih.gov/pubmed/32398042 http://dx.doi.org/10.1186/s13046-020-01564-4 |
Ejemplares similares
-
Targeting Prolactin Receptor (PRLR) Signaling in PRLR-Positive Breast and Prostate Cancer
por: O’Sullivan, Ciara C., et al.
Publicado: (2016) -
Association of prolactin receptor (PRLR) variants with prolactinomas
por: Gorvin, Caroline M, et al.
Publicado: (2019) -
Prolactin Receptor (PRLR) Isoform Expression in the Murine Oviduct
por: Radecki, Kelly C, et al.
Publicado: (2021) -
High Prolactin Concentration Induces Ovarian Granulosa Cell Oxidative Stress, Leading to Apoptosis Mediated by L-PRLR and S-PRLR
por: Yang, Ruochen, et al.
Publicado: (2023) -
A Novel Bispecific Antibody Targeting CD3 and Lewis Y with Potent Therapeutic Efficacy against Gastric Cancer
por: Chen, Jie, et al.
Publicado: (2021)